Resources to Help You Understand What Right-to-Try Legislation Means to You and Your Patients

May 29, 2018

With Congress having recently passed federal "right-to-try" (RTT) legislation, ASCO has developed a suite of educational resources that will help members understand the impact of this law on cancer care and individuals with cancer. Educational resources include:

The latest ASCO in Action Podcast  focuses on the right-to-try issue with guest ASCO Senior Vice President and Chief Medical Officer Dr. Richard Schilsky, FACP, FASCO, FSCT. The podcast, hosted by ASCO CEO Dr. Clifford A. Hudis, FACP, FASCO, examines RTT legislation and explains the difference between RTT and the Food and Drug Administration’s (FDA) expanded access program.

In addition to discussing the lack of patient protections under RTT measures, Dr. Schilsky points out that the term itself is a bit of a misnomer that gives a sense of false hope. “Right-to-try is a catchy phrase,” he says, “but it doesn’t actually provide patients with the right to try anything. It provides patients with the right to ask for a drug.”

Listen to the full discussion on your desktop, or through iTunes and Google Play.

Issue Brief
The ASCO in Action Brief: Right-to-Try  and Expanded Access to Investigational Drugs provides a comprehensive explanation of RTT legislation and is designed to help ASCO members gain a clearer understanding of the impact of the newly passed federal law on oncology patients and practices in the U.S. It underscores ASCO’s strong support for expanded access to investigational therapies outside of clinical trials in a framework that maintains critical FDA patient safeguards.  

The brief also points to resources aimed at facilitating conversations between health providers and patients on options to access investigational treatments outside of clinical trials, including  Cancer.Net, ASCO’s patient information website, and the Reagan-Udall Expanded Access Navigator.

Read the full brief.

Frequently Asked Questions (FAQ) on Right-to-Try and Expanded Access to Investigational Therapies
This FAQ document is a resource that physicians can share with patients who may have questions about accessing investigational therapies outside of a clinical trial either under Right-to-Try laws or through the FDA’s expanded access program.

Download the FAQ from the ASCO in Action Brief.

Visit ASCO in Action for the latest on right-to-try and other state and federal cancer policy priorities.